Drug facts
BrandTriumeq (Abacavir, Dolutegravir and Lamivudine)
No generic abacavir, dolutegravir and lamivudine is approved; the latest Triumeq patent or exclusivity in the Orange Book runs to 06/08/2030. 6 staged generic applications passed FDA review and wait on patents or exclusivity.
Triumeq was first approved by the FDA on 08/22/2014 under NDA 205551; the application holder is Viiv Healthcare Co.
The latest NADAC for TRIUMEQ 600-50-300 MG TABLET is $130.08 per unit (as of 10/28/2026).
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
1,316days until the latest patent expires
- Latest patent
- 06/08/2030Triumeq Orange Book
- Exclusivity
- 12/15/2026Triumeq Orange Book
02Competition
- Generics
- No generic approved Orange Book
- Staged generics
- 6 passed FDA review, awaiting market entry FDA
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $130.08 per unitTRIUMEQ 600-50-300 MG TABLET, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Viiv Healthcare Co Orange Book
- Application
- NDA 205551 Orange Book
- First approved
- 08/22/2014 Orange Book
- Dosage forms
- tablet
- Routes
- oral
- Other brand names
- Triumeq Pd
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.